Trial reportFrontiers in immunology2022
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- [Vaccination of immunocompromised individuals: Expert opinion - update 2026].Wiener klinische Wochenschrift · 2026Guideline
- Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.BMC geriatrics · 2024Pooled it
- Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.Human vaccines & immunotherapeutics · 2023Trial
- Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome.Human vaccines & immunotherapeutics · 2026Article
- Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein.Viruses · 2026Article
- Review
- Association of SARS-CoV-2 Serology Test Result and COVID-19 Vaccination in Adults: A Multisite Cohort Study.AJPM focus · 2025Article
- Article
- Antibody Response Against SARS-CoV-2 Spike Protein in People with HIV After COVID-19 Vaccination.Vaccines · 2025Article
- Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.Frontiers in immunology · 2025Article
- Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.Journal of functional biomaterials · 2024Review
- Review
- Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.Vaccines · 2024Article
- Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.Vaccines · 2024Article
- Article
- Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.Journal of clinical and translational hepatology · 2024Article
- A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.Gastroenterology & hepatology · 2024Article
- Safety and Immunogenicity of the ConvacellVaccines · 2024Article
- Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art.World journal of clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals with secondary immunodeficiencies belong to the most vulnerable groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination. However, knowledge about the persistence and anamnestic responses following SARS-CoV-2-mRNA vaccinations is limited in these patients. Methods: In a prospective, open-label, phase four trial we analyzed S1-specific IgG, neutralizing antibodies and cytokine responses in previously non-infected patients with cancer or autoimmune disease during primary mRNA vaccination and up to one month after booster. Results: 263 patients with solid tumors (SOT, n=63), multiple myeloma (MM, n=70), inflammatory bowel diseases (IBD, n=130) and 66 controls were analyzed. One month after the two-dose primary vaccination the highest non-responder rate was associated with lower CD19 Conclusion: Immunomonitoring of vaccine-specific antibody and cellular responses seems advisable to identify vaccination failures and consequently establishing personalized vaccination schedules, including shorter booster intervals, and helps to improve vaccine effectiveness in all patients with secondary immunodeficiencies. Trial registration: EudraCT Number: 2021-000291-11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.